ARTICLE | Top Story
ITMN buys Phase III antibiotic
September 20, 2001 7:00 AM UTC
InterMune (ITMN) acquired worldwide development, manufacturing and marketing rights to oritavancin from Eli Lilly (LLY) for $50 million. LLY also is eligible for milestones and royalties. Oritavancin ...